Digital

June 25-26, 2020

3rd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress - Virtual Event (Time Zone - ET)

45+

Speakers

200+

Attendees

4

Networking Hours

5+

Sessions

Due to growing concerns about COVID-19, the 3rd Annual MarketsandMarkets Next Gen IO Congress is going fully virtual this year. We are disappointed that we are not able to come together in person in June for this event, but we are so thrilled to see you on an online platform. We are working together to create a virtual conference that will be beneficial and engaging for speakers, attendees and sponsors/exhibitors.

See the Post Show report of our 2nd Annual here

Please write to [email protected] for questions regarding speaking, attending and sponsoring. We will keep you posted with the event flow soon. Keep checking our website.

WHAT TO EXPECT

Key Highlights

Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Monoclonal Antibody & Cellular Therapy
Neoantigens in personalized Cancer Immunotherapy
Biomarkers and Cancer Vaccines
Developments in CAR-T Cellular Therapy
Oncolytic Viral Therapy & Personalized Medicine
Engineering Cellular Therapies Beyond Traditional Tumor Antigens
Combination Therapies in I/O

Why attend Virtual?

Exclusive Virtual event to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
Find out new case studies of immune-oncology projects in development
Contribute to interactive Q&A sessions with your peers to deliberate key topics most relevant to you
Explore the latest platforms and technologies on the market for development
Discuss the best tool for your research in immune-oncology

CONFERENCE AGENDA

Day 1 Thu, 25-Jun-2020
Day 2 Fri, 26-Jun-2020

STREAM A - Targeted Antibodies & Cellular Therapy
STREAM B - Combination Therapies in I/O

Monoclonal Antibody & Cellular Therapy

Registration

Opening remark by Chairperson

Immunotherapy in 2020: Beyond checkpoint inhibition and CAR T cell

11:00 - 11:25 Geert Mudde, CSO and Managing Director, Founder, OncoQR ML GmbH, S-TARget therapeutics

Panel Discussion: The promises of CAR-T cell therapy in 2020 and beyond

Targeting AXL to leverage checkpoint immunotherapy: Updated results of the BGBC008 phase II study of bemcentinib and pembrolizumab in recurrent NSCLC

12:00 - 12:30 Hani Gabra , Chief Medical Officer , BerGenBio

Mechanisms of Resistance and Response to anti-CD19 CAR T cell Therapy in LC

12:30 - 12:55 John Rossi,, Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Targeting Bispecific Antibodies and Developing Systems Disease Models in I/O

12:55 - 13:25 John M. Burke, President, CEO, and Co-founder , Applied BioMath

REGN4018, a Mucin 16 bispecific T cell engaging antibody for the treatment of ovarian cancer

13:25 - 13:50 Alison Crawford, Associate Director of Immuno-oncology, Regeneron Pharmaceuticals, Inc.

Antibodies & CAR-T Cellular Therapy

Laboratory Considerations for Immuno-Oncology Clinical Trials - Q2 Solutions

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

14:05 - 14:30 Eric Halioua, President & CEO, PDC*line Pharma

Deciphering the function of B cells in human cancer

14:30 - 14:55 Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh

Closing remark by chairman

Networking│One-to-One Networking Meetings

End of Day 1

Advancing Precision Medicine: Emerging Therapeutic and Technological Approaches

Registration

Opening remark by Chairperson

Are there still unmet needs in ICI therapy?

11:00 - 11:25 Stefan Glueck, Ex- Vice President, Global Head Franchise Oncology, Regeneron

Cannabinoids as companion treatments for cancer

11:25 - 11:50 Philip Arlen, Chief Scientific Officer, Senior Vice President, Diverse Biotech

Solution Provider Presentation - Biocytogen

Solution Provider Presentation - Proteome Sciences

FDA Accelerated Approval Pathways for Cell and Gene Therapy

A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer

13:20 - 13:45 Indu Venugopal , Research Scientist, SRI International

Cancer Vaccines & Biomarkers

Solution Provider Presentation - PromoCell GmbH

First-in-class biotherapeutics, designed to “heat up” cold tumor microenvironment for combination therapy with PD(L)1 inhibitors

14:15 - 14:40 Christie Zhang , Project Team Leader, Elstar Therapeutics

Oncolytic Viruses: NOTCHing up the game

14:40 - 15:05 Balveen Kaur, Professor, The University of Texas Health Science Center

Closing remark by chairman

Networking│One-to-One Networking Meetings

End of Day 1

STREAM A - Targeted Antibodies & Cellular Therapy
STREAM B - Immune Checkpoint Inhibitors

Therapeutics antibodies & TCR-based Cellular Therapy

Registrations

Opening remark by Chairperson

PD-1 Antibodies are Transforming Cancer Care

11:00 - 11:25 Roy Baynes , Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

Development of a Next Generation Anti-Cancer Immunotherapy: A Humanized anti-BTN3A Antibody that Activates Gamma-Delta (Vg9-Vd2) T Cells

11:25 - 11:50 Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics

Novel serum-free and xeno-free T cell medium for improved T cell therapy manufacturing

Solution Provider Presentation - PhenoSwitch Bioscience Inc.

Completing the immune cycle by targeting novel macrophage checkpoints

12:50 - 13:15 Tatiana Novobrantseva, Co-founder and Chief Scientific Officer, Verseau Therapeutics

Solution Provider Presentation - PHC Corporation

Unleashing the Power of SQZ’d Cells to Engineer a New Generation of Cancer Vaccines

13:45 - 14:10 Katherine Seidl, Vice President Immunology Research and Development, SQZ Biotechnologies

Closing remarks from Chairman

Networking│One-to-One Networking Meetings

End of Conference

Registrations

Opening remark by Chairperson

Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy

11:00 - 11:25 Nuzhat Pathan, Director, Early Development, Translational and Immuno-Oncology, Pfizer

Cancer Immunotherapy: A Targeted, Personalized and Off-the-Shelf Approach

11:25 - 11:50 William Williams, President, CEO, Briacell Therapeutics Corporation

Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models

11:50 - 12:20 Bradlee Heckmann, CSO, Asha Therapeutics

Unleashing the power of NGS to unlock the secrets of immuno-oncology

12:20 - 12:50 Raed Samara Ph.D , Associate Director, Global Product Management, NGS , QIAGEN

Preventing drug resistance to targeted therapeutics in ER+HER2- Breast Cancer

12:50 - 13:15 Nathaniel Wang, Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson

Preclinical modeling of immune responses to Cancer: improving translatability of bench-side discoveries to clinical outcomes

13:15 - 13:40 Mithun Khattar, Immuno-Oncology Lead, Takeda Oncology

It’s time to look beyond Checkpoint Blockade

13:40 - 14:05 Shailesh Dudhgaonkar , Deputy Research Director , Biocon Bristol Myers Squibb R&D Center (BBRC)

Closing remarks from Chairman

Networking│One-to-One Networking Meetings

End of Conference

CONFERENCE SPEAKERS

Speakers

Shailendra Singh (Shelly)

Shailendra Singh (Shelly)
Board Member, MarketsandMarkets

Roy Baynes

Roy Baynes
Senior Vice President and Head Global Clinical Development, Chief Medical Officer, , Merck Research Laboratories

Mithun Khattar

Mithun Khattar
Immuno-Oncology Lead, Takeda Oncology

Stefan Glueck

Stefan Glueck
Ex- Vice President, Global Head Franchise Oncology, Regeneron

Nuzhat Pathan

Nuzhat Pathan
Director, Early Development, Translational and Immuno-Oncology, Pfizer

Philip Arlen

Philip Arlen
Chief Scientific Officer, Senior Vice President, Diverse Biotech

Nathaniel Wang

Nathaniel Wang
Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson

Shailesh Maingi

Shailesh Maingi
Founder and CEO, Kineticos Life Sciences

SPONSORS

Gold

example-image — BIOCYTOGEN

example-image — Applied BioMath

example-image — QIAGEN

Silver

example-image — PhenoSwitch Bioscience

Sponsors & Exhibitors

example-image — PromoCell

example-image — TransCure bioServices

example-image — BerGenBio

example-image — Imaging Endpoints

example-image — Q2 Solutions

example-image — CellGenix

example-image — Thermo Fisher Scientific

example-image — PHC Group

example-image — PHC Group

example-image — PHC Group

example-image — Proteome Sciences

example-image — Eppendorf

example-image — Cook Regentec

example-image — BioIVT

example-image — NeoGenomics

PAST EVENT GALLERY